Pfizer, a pharmaceutical firm, completed the acquisition of Biohaven Pharmaceuticals, a clinical-stage biopharmaceutical company, for $11.6bn. Biohaven common shareholders received $148.5 per share in cash representing a premium of approximately 33%. “Today’s announcement builds on our legacy of delivering breakthroughs for patients living with complex pain disorders and diseases that disproportionately impact women. NURTEC ODT, which is already the #1 prescribed migraine medicine in its class in the United States, coupled with Biohaven’s CGRP pipeline, offers hope for patients suffering from migraine worldwide. We believe Pfizer is uniquely positioned to help the portfolio reach its full potential given our leading scale and capabilities, including comprehensive field force engagement with Primary Care Physicians, specialists and health systems delivering the right information at the right time," Nick Lagunowich, Pfizer Global President.